XPATE
xpate , the rapidly-growing simplified cross-border payment solution provider, has announced a significant expansion of its disruptive developer team, with 35 new team members onboard to speed up building services aimed to enhance flexibility and data processing for merchants and acquirers.
The new appointments, with extensive experience at leading ecommerce platforms AliExpress, and enterprise cloud infrastructure builder Mirantis, will bring unrivalled levels of technical agility and creative user-focused design strengths to xpate.
The company’s ambitious growth plans, focused on helping customers to optimise payment flows and lower operational risk, have come to fruition over the last 12 months for the scaling company. The latest wave of developer hires takes xpate’s headcount to 135, from just three employees at the firm’s inception in 2018.
xpate’s momentum has been fuelled by the launch of breakthrough services such as its acquiring platform Links, and its Core Banking Solution (CBS) which speeds up and streamlines integration with various acquiring systems to give clients access to real-time data processing.
Supporting these services is xpate’s development of its own data warehouse, allowing the company to collect and store data in a centralised location to generate more deep analytics and reporting power for clients. Among the elevated service capabilities is the ability to offer businesses automatic reconciliation of third-party transactions, an internal monitoring and incident reporting system, and a customisable payment page for xpate’s merchants.
Mihails “Mike” Safro, CEO of xpate, comments: “The past three years have been something of a whirlwind, in terms of both the success of our product offerings and the growth of our team – specifically developers.
“Since xpate’s inception, we have worked tirelessly to build a company that combines technical ingenuity with a simplified user experience, to empower merchants to capitalise on all the opportunities in cross-border ecommerce. Our people are at the heart of our culture, and as such, we have assembled a diverse team of talented individuals who not only understand the importance of this ethos, but also offer unparalleled expertise and experience across the financial sector.
“While xpate has witnessed an incredible start to the business, we will certainly not be resting on our laurels. We are constantly working on improving our products and services, and look forward to sharing these exciting and ambitious developments with our customers throughout 2022 and beyond.”
These latest additions to the company’s team follow xpate achieving Mastercard principal member status in 2021 – a significant strategic partnership that has allowed xpate to enhance its platform, offer innovative solutions to new clients, bolster its merchant acquiring portfolio, and take advantage of an extended range of products and services to strengthen market offering.
For more information on xpate, go to: www.xpate.com .
###
About xpate
xpate is the payments platform that prioritises simplicity, speed and user experience.
We provide businesses with a single multi-fit solution that unites all of the desired payment methods to cover an extensive range of demands that otherwise require onboarding and integration with multiple partners.
#ENDS#
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005806/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release
Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release
Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release
New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
